Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWhy This Matters for Your Career
PharmaIN is hiring 1 role related to this product
Company
PharmaIN
WA - Bothell
PRAMIPEXOLE DIHYDROCHLORIDE (pramipexole dihydrochloride) by PharmaIN is non-ergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the d2 subfamily of dopamine receptors, binding with higher affinity to d3 than to d2 or d4 receptor subtypes. Approved for parkinson's disease, moderate-to-severe primary restless legs syndrome (rls). First approved in 2014.
Drug data last refreshed 19h ago
non-ergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. Parkinson's Disease The precise mechanism of action of pramipexole as a treatment for…
Worked on PRAMIPEXOLE DIHYDROCHLORIDE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride
Pramipexole Dihydrochloride 0.25 mg Tablets Under Non-Fasting Conditions
Pramipexole Dihydrochloride 0.25 mg Tablets Under Fasting Conditions
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPharmaIN is hiring 1 role related to this product